Evaluating a Parainfluenza Virus 5-Based Vaccine in a Host with Pre-Existing Immunity against Parainfluenza Virus 5
Evaluating a Parainfluenza Virus 5-Based Vaccine in a Host with Pre-Existing Immunity against Parainfluenza Virus 5
复制标题
DOI：
10.1371/journal.pone.0050144
复制
发表时间：
2012-11-20
期刊：
影响因子：
3.7
通讯作者：
He, Biao
中科院分区：
文献类型：
--
作者：
Chen, Zhenhai;Xu, Pei;He, Biao
副流感病毒5型（Parainfluenza virus 5，PIV 5），以前称为猴病毒5型（Simian virus 5，SV 5），是一种副粘病毒，在兽医领域通常称为犬副流感病毒（Canine Parainfluenza virus，CPI）。PIV 5被认为是犬舍咳嗽的一个促成因素。含有活PIV 5的犬舍咳嗽疫苗已在犬中使用了数十年。目前还不知道PIV 5会在人类或其他动物中引起任何疾病。PIV 5已被用作人类和动物疫苗开发的载体。关于使用PIV 5作为载体的一个关键问题是，既往暴露于PIV 5是否会阻止使用基于PIV 5的疫苗。在这项工作中，我们已经检查了表达甲型流感病毒亚型3（rPIV 5-H3）的血凝素（HA）的重组PIV 5在对PIV 5免疫的犬中的免疫原性。我们发现，用rPIV 5-H3接种含有抗PIV 5中和抗体的犬可产生抗甲型流感病毒的免疫力，表明基于PIV 5的疫苗在既往暴露的犬中具有免疫原性。此外，我们还检查了人群中的PIV 5暴露。我们在45份人血清样本中的13份（约29%）中检测到抗PIV 5的中和抗体（nAb）。人体nAb滴度低于接种犬，表明人体nAb不太可能阻止PIV 5成为人体有效载体。
Parainfluenza virus 5 (PIV5), formerly known as simian virus 5 (SV5), is a paramyxovirus often referred to as canine parainfluenza virus (CPI) in the veterinary field. PIV5 is thought to be a contributing factor to kennel cough. Kennel cough vaccines containing live PIV5 have been used in dogs for many decades. PIV5 is not known to cause any diseases in humans or other animals. PIV5 has been used as a vector for vaccine development for humans and animals. One critical question concerning the use of PIV5 as a vector is whether prior exposure to PIV5 would prevent the use of PIV5-based vaccines. In this work, we have examined immunogenicity of a recombinant PIV5 expressing hemagglutinin (HA) of influenza A virus subtype 3 (rPIV5-H3) in dogs that were immunized against PIV5. We found that vaccination of the dogs containing neutralizing antibodies against PIV5 with rPIV5-H3 generated immunity against influenza A virus, indicting that PIV5-based vaccine is immunogenic in dogs with prior exposure. Furthermore, we have examined exposure of PIV5 in human populations. We have detected neutralizing antibody (nAb) against PIV5 in 13 out of 45 human serum samples (about 29 percent). The nAb titers in humans were lower than that in vaccinated dogs, suggesting that nAb in humans is unlikely to prevent PIV5 from being an efficacious vector in humans.